A team led by private equity lawyer Dr. Andreas Lenz, Partner at the Cologne office, advised Lenbach Equity Opportunities I SCSp, a Luxemburg-based PE fund, on the sale of Lomapharm group.
Lomapharm group’s core company is Lomapharm KG with over 140 years of tradition in pharmaceutical manufacturing. Lomapharm specializes in the development and manufacture of pharmaceuticals, food supplements, and medical products on behalf of pharmaceutical companies. It also manufactures related packaging (glass, plastic, and cardboard).
Following a structured sale process, Japan-based DAICEL Corporation, listed on the Tokyo Stock Exchange, finally acquired Lomapharm group.
The transaction became effective on September 28, 2018 following approval by the German Federal Cartel Office and after meeting additional conditions.
Counsel to Lenbach Equity Opportunities I SCSp
Heuking Kühn Lüer Wojtek:
Dr. Andreas Lenz,
Ralph M. Schnaittacher (both Lead, M&A),
Dr. Katharina Prasuhn,
Dr. Vera Randel,
Bastian Rieck (all Corporate/M&A),
Dr. Sascha Schewiola (Employment, Pensions), all Cologne
Beatrice Stange, LL.M. (Merger Control), Düsseldorf
Dr. Markus Collisy (Public Law / Environment), Frankfurt